ACE-031 vs Follistatin 344
A side-by-side research comparison of ACE-031 and Follistatin 344 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ACE-031 | Follistatin 344 |
|---|---|---|
| Full name | ACE-031 (Soluble ActRIIB-Fc Fusion) | Follistatin 344 (FST-344) |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational | Research compound |
| Mechanism | Decoy receptor sequestering TGF-B ligands (myostatin, activin, GDF-11) in bloodstream, preventing cell-surface ActRIIB binding and removing multiple anabolic brakes. | Binds myostatin and activin A with high affinity, preventing ActRIIB receptor activation. Removes the brake on muscle growth allowing uninhibited satellite cell proliferation. |
| Molecular weight | ~90,000 Da | 36,000 Da |
| Half-life | 10-14 days | 2-4 hours |
| Bioavailability | High (SubQ) | Moderate (SubQ) |
| Typical dose | 0.3-3 mg/kg | 100-200 mcg |
| Frequency | Every 2-4 weeks | Daily for 10-30 days |
| Route | Subcutaneous | Subcutaneous |
ACE-031 reported benefits
- Multi-ligand pathway inhibition
- Lean mass increase
- Bone density increase
- Infrequent dosing
- Functional strength improvement
Follistatin 344 reported benefits
- Significant muscle growth
- Myostatin inhibition
- Increased strength
- Activin neutralization
- Enhanced recovery
Related comparisons
Research and educational reference only. Not medical advice.